Mass General Brigham Program

Program Identity & Fit

This is a newly merged, ultra-elite academic pathology residency uniting two historically independent powerhouse programs—Brigham and Women's Hospital and Massachusetts General Hospital—both Harvard-affiliated, into a single joint training experience with 21 residents per class rotating between both flagship quaternary-care sites. Research is not merely supported but structurally embedded: dedicated T32 physician-scientist pathways (Oncopathology Training Program at BWH, Molecular Immunology and Tumor Biology Program at MGH), an American Board of Pathology Physician-Scientist Research Pathway open to any resident, longitudinal research mentorship beginning in year one, and access to the Broad Institute, Dana-Farber, and Harvard Catalyst signal an identity built around producing academic leaders and investigators. The program explicitly values residents who will engage with translational research (immunohistochemistry through next-generation sequencing and mass spectrometry) even if they intend community practice, while emphasizing interactive, case-based joint didactics and cross-institutional collaboration reflecting its dual-site, integrated-enterprise structure. Career outcomes are oriented toward academic pathology, subspecialty fellowship training, and physician-scientist careers, with the merger itself framed as building a broader, more resourced training ecosystem than either legacy program alone.